Skip to main content

Table 1 Patient and healthy control characteristics at baseline

From: Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis

Clinical and laboratory data

Patients

n = 41

Healthy controls

n = 22

p value

Women/men (% women)

32/9 (78%)

17/5 (77%)

0.9

Agea (years)

31 (24–36)

32 (26–41)

0.3

Diagnosis (CIS/RRMS)

19/22

N/A

 

Relapse within last 2 months (yes/no)

23/18

N/A

 

Mean disease durationb (months)

11.8

N/A

 

Median disease durationb (months)

3.5

N/A

 

Disease durationb (number of subjects)

 

N/A

 

 0–1 months

10

  

 1.25–2 months

7

  

 2.25–3 months

3

  

 3.25–6 months

6

  

 6.5–12 months

7

  

 13–24 months

3

  

 25–36 months

2

  

 37–48 months

1

  

 49–120 months

2

  

Median EDSS

2.0

N/A

 

EDSS (number of subjects)

 0

6

22

 

 1.0

12

  

 1.5

2

  

 2.0

12

  

 2.5

3

  

 3.0

1

  

 3.5

2

  

 4.0

2

  

 4.5

1

  

CSF mononuclear cell counta

4.6 × 106/L (1.8–9.2)

2.1 × 106/L (0.9–2.7)

0.001

Albumin ratioa

4.8 (3.4–6.0)

4.7 (3.6–5.3)

0.5

IgG indexa

0.7 (0.5–1.1)

0.5 (0.5–0.5)

< 0.001

IgG synthesis indexa

1.3 (1.0–2.1)

0.9 (0.9–1.0)

< 0.001

Oligoclonal CSF IgG bands (pos/neg)

33/8

0/22

< 0.001

  1. p values from chi-square test for sex distribution and oligoclonal bands and from Mann-Whitney U test for age and CSF data
  2. N/A not applicable, DMT disease-modifying treatment
  3. aMedian and within brackets interquartile range
  4. bDisease duration refers to time from first symptom suggestive of demyelinating disease